Loading...
•
Dec 31, 2020
Eagle Q4 2020 Earnings Report
Reported strong earnings with adjusted non-GAAP earnings growth.
Key Takeaways
Eagle Pharmaceuticals reported a strong earnings year with a 36% year-over-year growth, despite challenges from the COVID-19 pandemic. The company's balance sheet remains healthy, supporting development programs and future growth. Key pipeline products like vasopressin, fulvestrant, and Ryanodex for nerve agent exposure show significant opportunities.
Q4 2020 net income was $0.62 per basic and $0.60 per diluted share.
Adjusted non-GAAP net income for Q4 2020 was $0.98 per basic and $0.96 per diluted share.
Total revenue for Q4 2020 was $49.9 million.
Gross Margin was 75% during the fourth quarter of 2020.
Eagle
Eagle
Eagle Revenue by Segment
Revenue by Segment
BELRAPZO product sales Revenue
CapyFin.comRYANODEX product sales Revenue
CapyFin.comRoyalty Revenue
CapyFin.comRevenue & Expenses
Visualization of income flow from segment revenue to net income